Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Telix lifts FY2026 revenue guidance above $1 billion on strong Q2 momentum

Jul 20, 2026, 7:33 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The quarter's strong revenue growth, reaffirmed >$1B guidance, and a $40M upfront from Regeneron improve visibility on cash flow and R&D funding, likely supporting a near-term stock move.

AI summary

What happened, with direct paths to the underlying reporting

Telix reported Q2 2026 revenue of US$247 million, up 7% QoQ and 21% YoY, led by Precision Medicine. The company reaffirmed FY2026 revenue guidance above US$1 billion, aided by a US$40 million upfront from Regeneron and FDA alignment enabling ProstACT Part 2. Ongoing PSMA imaging and Theranostics expansion could sustain upside into 2027.

Group revenue US$247M; QoQ +7%, YoY +21%.
Precision Medicine revenue US$202M; QoQ +9%, YoY +30%.
FY2026 revenue guidance >US$1B; includes US$40M Regeneron income.
FDA alignment on ProstACT Phase 3; Part 2 initiation anticipated.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Telix lifts FY2026 revenue guidance above $1 billion on strong Q2 momentum

Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent